Indication: Solid Tumors

Phase 1 Study To Evaluate The Safety And Pharmacokinetics Of Palbociclib (Ibrance®) In Combination With Irinotecan And Temozolomide In Pediatric Patients With Recurrent Or Refractory Solid Tumors

Sub-indication: Solid Tumors

Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Pfizer

Search our entire site.